AstraZeneca Loses Final Bid For Additional Seroquel Exclusivity
This article was originally published in The Pink Sheet Daily
An appeals court finds FDA acted reasonably in denying AstraZeneca’s request for three years of marketing exclusivity for data it submitted for inclusion in Seroquel labeling.
You may also be interested in...
New round of orders would give the US all the vaccine it needs from the existing mRNA products, taking pressure off AstraZeneca as it experiences manufacturing challenges and the EU considers export restrictions to ensure it gets enough vaccine.
US FDA final guidance describes possible study design to test whether selected names may misbrand a drug. Agency also okays use of two-letter USAN stems in product names and clarifies use of modifiers.
FDA’s Amy Abernethy describes how agency’s use of real-world data has evolved in response to COVID-19 and the ‘a-ha’ moment of leveraging different data sources to understand the coronavirus. Takeda R&D President Andrew Plump notes difficulties with platform trials and limitations on data sharing.